CORAL GABLES, Fla., March 5, 2015 (GLOBE NEWSWIRE) — Catalyst Pharmaceutical Partners, Inc. (Nasdaq:CPRX), (Catalyst Pharmaceuticals), a biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted the company orphan drug designation for Firdapse™ for treatment of patients with Congenital Myasthenic Syndromes (CMS).

Read the full text here: http://ir.catalystpharma.com/releasedetail.cfm?ReleaseID=900213

Leave a comment

CORAL GABLES, Fla., Feb. 19, 2015 (GLOBE NEWSWIRE) — Catalyst Pharmaceutical Partners, Inc. (Nasdaq:CPRX), (Catalyst Pharmaceuticals), a biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating diseases, today announced the appointment of Richard J. Daly and Donald A. Denkhaus to the Company’s Board of Directors.

“Catalyst is pleased to welcome such exceptional and successful pharmaceutical business leaders to its board, adding additional financial, operational and commercial expertise as we transform from a clinical stage company to a commercial operation,” said Patrick J. McEnany, Chairman and CEO of Catalyst.

Read the full text here: http://ir.catalystpharma.com/releasedetail.cfm?ReleaseID=897261

Leave a comment

CORAL GABLES, Fla., Feb. 9, 2015 (GLOBE NEWSWIRE) — Catalyst Pharmaceutical Partners, Inc. (Nasdaq:CPRX) (Catalyst Pharmaceuticals) today reported that it has closed its previously announced public offering of shares of its common stock. The Company sold 11,500,000 shares of its common stock in the offering, which includes 1,500,000 shares that were issued upon the full exercise by the underwriters of their over-allotment option. The offering price was $3.25 per share, and the net proceeds from the sale of the shares is expected to be approximately $34.7 million. Piper Jaffray & Co. acted as the sole lead book-running manager and SunTrust Robinson Humphrey acted as the passive book-running manager with respect to this offering. Further, Roth Capital Partners and H.C. Wainwright & Co. acted as the lead co-manager and co-manager, respectively.

Read the full text here: http://ir.catalystpharma.com/releasedetail.cfm?ReleaseID=895404

Leave a comment

Catalyst Pharmaceutical Partners, Inc. (Nasdaq:CPRX) (Catalyst Pharmaceuticals) announced the pricing of its previously announced underwritten public offering of 10,000,000 shares of its common stock at an offering price of $3.25 per share. In connection with the offering, Catalyst has also granted the underwriters a 30-day option to purchase up to an additional 1,500,000 shares of common stock to cover over-allotments, if any.

Read the full text here: http://ir.catalystpharma.com/releasedetail.cfm?ReleaseID=894640

Leave a comment

Catalyst Pharmaceutical Partners, Inc. (Nasdaq:CPRX) announced today that it intends to offer shares of its common stock in a public offering. Catalyst also expects to grant the underwriters a 30-day option to purchase additional shares of its common stock to cover over-allotments, if any. Catalyst plans to use the net proceeds from the offering (i) to pay milestone payments due on final approval of an NDA for Firdapse™; (ii) to pay pre-commercialization and other expenses required to launch Firdapse™; (iii) to fund future clinical studies of Firdapse™ for other indications, to the extent that such additional studies are required; (iv) to fund future clinical and nonclinical studies of CPP-115; and (v) for general corporate purposes.

Read the full release here: http://ir.catalystpharma.com/releasedetail.cfm?ReleaseID=894494

Leave a comment

CORAL GABLES, Fla., Feb. 2, 2015 Catalyst Pharmaceutical Partners, Inc. (Nasdaq:CPRX), (Catalyst Pharmaceuticals), a biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating diseases, today announced it has held a productive pre-New Drug Application (NDA) meeting with the U.S. Food and Drug Administration (FDA) regarding Firdapse™ for the treatment of LEMS. Based on this meeting, Catalyst believes that its Phase 3 clinical program will provide acceptable support for submission of an NDA for Firdapse for LEMS.

Read the full release here:

http://ir.catalystpharma.com/releasedetail.cfm?ReleaseID=894028

Leave a comment
  • Pre-NDA Meeting with the FDA
  • Firdapse NDA Submission
  • Developing Regulatory Strategy for Firdapse for Congenital Myasthenic Syndrome
  • Hosting 1×1 Meetings in San Francisco January 12-15

Catalyst Pharmaceutical Partners, Inc. today announced the company’s 2015 goals for its product portfolio. The Company will be hosting 1×1 meetings this week in conjunction with The Trout Group Management Access Conference in San Francisco, January 12-15. The Company’s presentation materials will be available on the “Investors” section of the Company’s website, www.catalystpharma.com.

Read the release here: http://ir.catalystpharma.com/releasedetail.cfm?ReleaseID=890746

Leave a comment

Catalyst Pharmaceutical Partners, Inc. today announced that Patrick J. McEnany, Chief Executive Officer, and Steven Miller, Ph.D., Chief Operating Officer and Chief Scientific Officer, will present at the Piper Jaffray 26th Annual Healthcare Conference held at The New York Palace Hotel in New York City, Dec. 2-3. The presentation is scheduled for Tuesday, Dec. 2 at 12:00 p.m. EST. The presentation materials will be posted at www.catalystpharma.com in the Investors section under Events & Presentations.

Read the release here: http://ir.catalystpharma.com/releasedetail.cfm?ReleaseID=885310

DISCLAIMER: Catalyst Pharmaceutical Partners, Inc. (Catalyst) is covered by the analysts at various brokerage firms that issue reports on the company.  Please note that any opinions, estimates or forecasts regarding Catalyst’s performance, clinical trials, company, management, competitors, forecasts made by these analysts are theirs alone and do not represent opinions, estimates or forecasts of Catalyst or its management. Catalyst does not by its reference above or distribution imply, and expressly disclaims, any endorsement of or concurrence with any information, estimates, forecasts, opinions, conclusions or recommendations provided by analysts.

Leave a comment

Catalyst Pharmaceutical Partners, Inc., a biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating diseases, today announced that the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance for U.S. Patent Application Serial Number 13/581,187. The patent application is generally directed to methods reducing visual field defects and intramyelinic edema resulting from the use of a GABA-aminotransferase inhibitor by using CPP-115, a new and novel GABA-AT inactivator, to treat neurological or psychological disorders.

Read the release here: http://ir.catalystpharma.com/releasedetail.cfm?ReleaseID=884518

 

DISCLAIMER: Catalyst Pharmaceutical Partners, Inc. (Catalyst) is covered by the analysts at various brokerage firms that issue reports on the company.  Please note that any opinions, estimates or forecasts regarding Catalyst’s performance, clinical trials, company, management, competitors, forecasts made by these analysts are theirs alone and do not represent opinions, estimates or forecasts of Catalyst or its management. Catalyst does not by its reference above or distribution imply, and expressly disclaims, any endorsement of or concurrence with any information, estimates, forecasts, opinions, conclusions or recommendations provided by analysts.

Leave a comment

Catalyst Pharmaceutical Partners, Inc. reported financial results for the third quarter and nine months ended September 30, 2014.

Read the full release here: http://ir.catalystpharma.com/releasedetail.cfm?ReleaseID=883057

 

DISCLAIMER: Catalyst Pharmaceutical Partners, Inc. (Catalyst) is covered by the analysts at various brokerage firms that issue reports on the company.  Please note that any opinions, estimates or forecasts regarding Catalyst’s performance, clinical trials, company, management, competitors, forecasts made by these analysts are theirs alone and do not represent opinions, estimates or forecasts of Catalyst or its management. Catalyst does not by its reference above or distribution imply, and expressly disclaims, any endorsement of or concurrence with any information, estimates, forecasts, opinions, conclusions or recommendations provided by analysts.

Leave a comment
Follow

Get every new post delivered to your Inbox.

Join 234 other followers

%d bloggers like this: